News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News ThePatientsGuide.co.uk Launches Dedicated Migraine Guide to Help Patients Better Understand Their Condition News Pineapple Financial Reports Fiscal Q1 2026 Financial Results and Introduces FY 2026 Outlook and DAT Update News Ciscom Announces A Revenue Rebound, An Enhanced Digital Offering And A Positive Outlook for 2026 News LQWD Announces Closing of Non-Brokered Private Placement News Gatekeeper Commences $27M LIRR Project, Provides Anticipated Revenue Schedule News Paragon Advanced Labs and Scout Discoveries Announce Partnership Agreement to Set a New Standard for Exploration Speed
